A genetic model for central chondrosarcoma evolution correlates with patient outcome


Central conventional chondrosarcoma (CS) is the most common primary malignant bone tumour in adults. Anatomical location, histopathology, and grading are the current criteria for determining treatment [1, 2], although providing prognoses remains challenging [1–3]; hence, a greater understanding of the disease, and its biomarkers is required to provide patients with a more personalized treatment plan.

Click here to read the full commentary